Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
Open Access
- 11 December 2002
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 119 (4) , 976-984
Abstract
Summary. We evaluated the efficacy and toxicity of fludarabine combined with cyclophosphamide and mitoxantrone (FCM) in patients with relapsed or resistant chronic lymphocytic leukaemia (CLL). In total, 37 patients with recurrent or resistant CLL received FCM: fludarabine 25 mg/m2 intravenously (IV), d 1–3; cyclophosphamide 200 mg/m2 IV, d 1–3; and mitoxantrone 6 mg/m2 IV, d 1, at 4‐week intervals for up to six courses. Moreover, 23 patients received FCM with cyclophosphamide 600 mg/m2 i.v. and mitoxantrone 8 mg/m2 i.v. on d 1. In addition to clinical methods, response was assessed using cytofluorometric and molecular techniques. ‘In vitro’ sensitivity to the FCM regimen was also analysed in 20 samples. The median number of courses given was 3 (range: 1–6). Overall, 30 patients (50%) achieved complete response (CR), including 10 cases of negative minimal residual disease (MRD(–)) (17%), and 17 (28%) partial response (PR). The median duration of response was 19 months. ‘In vitro’ sensitivity also correlated with CR achievement (P = 0·04). Main toxicity consisted of neutropenia, infections (8% of courses), and nausea and vomiting. The treatment‐related mortality was 5%. FCM did not hamper stem cell harvesting in patients who were candidates for autologous stem cell transplantation. FCM induced a high CR rate, including an important number of MRD(–), in patients with previously treated CLL.Keywords
This publication has 28 references indexed in Scilit:
- Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupBritish Journal of Haematology, 2001
- Does Intensive Treatment with High Dose Chlorambucil and Prednisone as First Line and Cladribine as Second Line Influence the Survival of the Patients with Chronic Lymphocytic Leukemia?Leukemia & Lymphoma, 2001
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapyEuropean Journal of Haematology, 1998
- Combined therapy with Fludarabine and Cyclophosphamide in relapsed/resistant patients with B‐cell chronic lymphocytic leukaemia and non‐Hodgkin's lymphomasEuropean Journal of Haematology, 1997
- Fludarabine in Resistant or Relapsing B-Cell Chronic Lymphocytic LeukemiaThe Spanish GroupExperienceLeukemia & Lymphoma, 1996
- Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1995
- Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemiaEuropean Journal of Haematology, 1993
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958